Investing.com - Fortress Biotech reported on Monday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Fortress Biotech announced earnings per share of $-0.250 on revenue of $16.53M. Analysts polled by Investing.com anticipated EPS of $-0.270 on revenue of $20.84M.
Fortress Biotech shares are down 30% from the beginning of the year and are trading at $0.857 , down-from-52-week-high.
Fortress Biotech follows other major Healthcare sector earnings this month
Fortress Biotech's report follows an earnings beat by J&J on October 18, who reported EPS of $2.55 on revenue of $23.79B, compared to forecasts EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on November 1 with third quarter EPS of $1.98 on revenue of $6.94B, compared to forecast for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar